1596 related articles for article (PubMed ID: 7554977)
21. Hormonal profile of the menstrual cycle in Chinese women after tubal sterilization.
Wu E; Xiao B; Yan W; Li H; Wu B
Contraception; 1992 Jun; 45(6):583-93. PubMed ID: 1617967
[TBL] [Abstract][Full Text] [Related]
22. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
23. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
Nilsson CG; Lähteenmäki P; Luukkainen T
Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
[TBL] [Abstract][Full Text] [Related]
24. Hormonal evaluation and midcycle detection of intrauterine glycodelin in women treated with levonorgestrel as in emergency contraception.
Durand M; Koistinen R; Chirinos M; Rodríguez JL; Zambrano E; Seppälä M; Larrea F
Contraception; 2010 Dec; 82(6):526-33. PubMed ID: 21074015
[TBL] [Abstract][Full Text] [Related]
25. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
26. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
27. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
28. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
29. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
30. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
31. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
32. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
[TBL] [Abstract][Full Text] [Related]
33. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD.
Jia MC; Zhou LY; Ren S; Dong L; Xiao B
Adv Contracept; 1992 Mar; 8(1):33-40. PubMed ID: 1590100
[TBL] [Abstract][Full Text] [Related]
34. Hormonal profile in IUD users.
Souka AR; Rahman H; Osman M; Mohei Y; Rizk M
Contracept Deliv Syst; 1981 Oct; 2(4):303-10. PubMed ID: 12336991
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
36. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
37. Endometrial angiogenic response in Norplant users.
Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
[TBL] [Abstract][Full Text] [Related]
38. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
[TBL] [Abstract][Full Text] [Related]
40. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
